Fortitude Family Office’s VYNE Therapeutics VYNE Stock Holding History
Bought
Maintained
Sold
Other funds holding VYNE
SC
AFM
NCM
TC
KCA
IC
ACM
Fortitude Family Office's VYNE Position: Q4 2025 in Review
Fortitude Family Office sold out of VYNE Therapeutics (VYNE) in Q4 2025, closing a stake of 14 shares — an estimated $228 sold.
Fortitude Family Office first reported a position in VYNE in Q3 2025 and held it in 1 quarter. The position peaked at $228 in Q3 2025. 41 funds tracked by Wall St. Rank hold VYNE as of Q4 2025.
- Fortitude Family Office reported no remaining VYNE Therapeutics position as of Q4 2025 after selling out during the quarter.
- Fortitude Family Office sold 14 VYNE Therapeutics shares in Q4 2025, an estimated $228.
- Fortitude Family Office first reported a position in VYNE Therapeutics in Q3 2025 and held it in 1 quarter.
- Fortitude Family Office's VYNE Therapeutics position peaked at $228 in Q3 2025.
- 41 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2025.
Based on Fortitude Family Office's 13F filing for Q4 2025, filed 15 Jan 2026.